Skip To Main Content
Orlan K. Macdonald on Muck Rack

Orlan K. Macdonald

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Orlan K.

Contact Orlan K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study

|
By Kevin Flanagan, Jon Earls, Jeffrey Hiken, Rachel L. Wellinghoff, Kyle Pemberton, Andrew Pippas, Karl J. D’Silva, Warren Alexander, Samuel Bailey, Georges El Azzi, Paul Gonzales, James Wade III, Jessica A Hellyer, Howard McLeod, Eric J. Duncavage, Jarret Glasscock, Michelle M. Ponder, Orlan K. Macdonald, Karim Welaya, Xingwei Sui, Jennifer Slim, Steven J. Saccaro, Todd D. Shenkenberg, Scott A. Sonnier, Steven E. Kossman
| Nature Verified
Abstract Lung cancer remains the leading cause of cancer mortality worldwide. Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 have significantly improved outcomes in a subset of patients. OncoPrism, a clinical test employing a multidimensional predictive RNA-based immune biomarker, was evaluated for predicting immune checkpoint inhibitor benefit in non-small cell lung cancer (NSCLC) patients.
Open in Who Shared Issue with article?
See all 1 articles